Pharmacology

Action Mechanism of Action Reference
BINDING AGENT B-lymphocyte antigen CD19 binding agent FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma 4 D008223 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 4 D016403 FDA
Lymphoma, Follicular 3 D008224 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Leukemia, Prolymphocytic 2 D015463 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4298047
FDA SRS QQA9MLH692